Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch

TLDR Scienture (NASDAQ: SCNX) jumped 355% to $2.60 on October 23, 2025, after launching Arbli, the first FDA-approved liquid losartan suspension. The stock showed extreme volatility, dropping 25% in after-hours trading and swinging between $0.83 and $2.60 the following day. Arbli targets a $256 million U.S. market with 71 million annual losartan prescriptions, serving patients [...]

The post Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch appeared first on Blockonomi.